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6 Peanut allergy (PA) is associated with marked quality-of-life (QoL) impairment. However, data are 
7 lacking on the experience and impact of living with PA from the perspectives of persons with PA 
8 (PwPA) and their caregivers. Allergy to Peanuts imPacting Emotions And Life study 1 (APPEAL-1) 
9 was a pan-European survey investigating these perspectives. This first of two articles reports clinical 
10 characteristics of PwPA and PA management practices. 
11 Methods 
12 APPEAL-1 was a quantitative, online survey conducted in eight European countries, developed by 
13 eight representatives of patient advocacy groups and five healthcare professionals and researchers. 
14 Eligible participants included adults with PA and parents/caregivers of PwPA who responded by self-
15 report and provided proxy-report for the PwPA under their care. Data were summarised using 
16 nonweighted descriptive statistics. 
17 Results
18 Of 1846 completed/analysed questionnaires, 528 were from adults with PA (self-report); 437 by 
19 proxy for children with PA (34 aged 0-3 years, 287 aged 4-12 years, 116 aged 13-17 years); 881 from 
20 parents/caregivers (self-report). Of PwPA (N=965), 95% reported diagnosis by healthcare 
21 professionals, mostly by clinical history and peanut-specific allergy testing. Rates of allergic rhinitis, 
22 asthma, and other food allergies in PwPA were 50%, 42%, and 79%, respectively. Only 31% of 
23 PwPA received HCP advice/support following their worst allergic reaction, and 28% had not been 
24 prescribed an adrenaline auto-injector. Results were similar by country but varied by age group. 
25
26 Conclusions
27 The APPEAL-1 findings contribute to greater understanding of PA impact on PwPA, caregivers, and 
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1 INTRODUCTION
2 Peanut allergy (PA) is a common and potentially life-threatening condition that imposes a significant 
3 burden of illness.1,2 Utilising various methods of detection and diagnosis, including self-report, 
4 prevalence estimates for PA in European countries reach up to 2.8%, with estimates higher among 
5 older age cohorts than in younger children, and in Western versus other areas of Europe.3-5 Increases 
6 in PA prevalence have been reported in the United Kingdom (UK) and the United States (US), 
7 although the reasons for these trends are unclear.6-8 Symptoms of PA typically begin between one and 
8 two years of age and persist through adulthood in ~80% of patients, in contrast to milk and egg 
9 allergies that are more likely to resolve in childhood.1,2,9-11 
10
11 Multiple factors contribute to the burden of PA.12,13 Compared with other food allergies, PA is 
12 associated with higher rates of severe reactions and incidence of anaphylactic events requiring 
13 emergency care in Western nations.14-18 and is an elicitor of anaphylaxis from infancy through 
14 adolescence.17 PA is also responsible for the highest proportion of fatal food-related anaphylaxis in 
15 most studies.19-21 The widespread use of peanut in a broad range of food products; inaccurate, 
16 incorrect or absent labeling; misreading of labels by persons with PA (PwPA) or caregivers; 
17 manufacturing errors; and inadvertent contamination also contribute to high rates of accidental 
18 exposure to peanut.22 Accidental exposures have been reported to occur in ~13% of Canadian peanut-
19 allergic children.22-24 and 48% of children and adolescents in the UK annually, among whom ~25% of 
20 the reactions were anaphylaxis.25 In addition, up to 95% of PwPA have at least one comorbid allergic 
21 condition, such as asthma, atopic dermatitis, or another food allergy.26 
22
23 The standard of care for PA and other food allergies consists of avoidance of trigger foods and the use 
24 of rescue medication (i.e. adrenaline autoinjector [AAI]) in case of accidental exposure. 27-29 
25 However, dietary avoidance itself can be a major source of anxiety, stress and impaired health-related 
26 quality of life (HRQL).13,30,31 Research data in food-allergic and PA populations also indicate that 
27 having been prescribed an AAI, and having to use it, are independently associated with decreased 
28 HRQL related to fear and uncertainty regarding use of the device, the burden of carrying it, and the 









This article is protected by copyright. All rights reserved
1 food allergies, in general, have strong adverse impacts on the HRQL of patients, parents and 
2 caregivers.13,30,31,34-42 However, there is a lack of multi-country, cross-sectional studies on the 
3 epidemiologic and psychological factors that provide context for, and may help explain, the impact 
4 and burden of PA.43,44 
5
6 APPEAL (Allergy to Peanuts imPacting Emotions And Life) is a two-part study conducted across 
7 Europe to comprehensively evaluate the burden and psychosocial impact of living with PA. APPEAL-
8 1 is a quantitative, cross-sectional, online survey study conducted in eight European countries to 
9 comprehensively assess multiple interactive domains of the experiences of PwPA, including adults 
10 and children, as well as parent/nonparent caregivers, hereafter referred to in this report as 
11 “caregivers.” Major survey components include demographic factors, clinical characteristics and 
12 history, and experiences with healthcare professionals (HCPs); the day-to-day experience of living 
13 and coping with PA; and impacts of PA on psychosocial parameters and quality of life. While other 
14 studies have assessed HRQL in patients with food allergies across European countries,38,39 to our 
15 knowledge, APPEAL is the first such study focused on the PA population that evaluates a comparably 
16 broad spectrum of factors involved in the burden of PA. Other distinctive features of APPEAL-1 
17 include a large multinational cohort of patients with PA across Europe; perspectives of peanut-allergic 
18 individuals (adults and children) as well as caregivers; and analysis by age groups and country. In this 
19 first of two articles describing the results of APPEAL-1, we report data collected directly from PwPA 
20 and caregivers focusing on clinical history, diagnosis and management of PA. A tandem article 




25 APPEAL-1 was conducted in Denmark, France, Germany, Ireland, Italy, the Netherlands, Spain, and 
26 the UK. It consisted of a 30-minute online survey initially written in English, translated/back-
27 translated into 6 other languages (Danish, Dutch, French, German, Italian, and Spanish), and adapted 
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1 questionnaire and study protocol were developed by the APPEAL advisory board, which was 
2 comprised of representatives of eight patient advocacy groups (PAGs; one from each of the eight 
3 countries represented in the study) and a specialist panel that included five HCPs and research 
4 specialists. Ethical approval was obtained from the Freiburg Ethics Commission International 
5 (Universitätsklinikum Freiburg; https://www.uniklinik-freiburg.de/ethics-commission.html). 
6
7 Study population 
8 APPEAL-1 participants were recruited through the PAGs or by a professional recruitment service for 
9 research studies. The PAGs operated independently of each other, using varied methods for 
10 recruitment, such as announcements on websites or direct email contact to registered individuals who 
11 had previously given consent to be contacted for research purposes. The recruitment service contacted 
12 individuals in its database who had expressed willingness to participate in online studies and had an 
13 interest in allergy and/or health issues. Individuals recruited through the recruitment service received 
14 compensation for participating; the individuals recruited via the PAGs did not. 
15
16 Eligible participants included adults (aged ≥18 years) diagnosed with PA who responded for 
17 themselves (self-report) and adult caregivers of PwPA (adult or child) who responded regarding the 
18 impact of PA on themselves (self-report) (Figure 1). The caregivers were also invited to answer a 
19 survey on behalf of the PwPA under their care (proxy-report) (Figure 1). Thus, the total number of 
20 potential responses was higher than the total number of participants. All participants had to be 
21 residents of one of the eight countries and willing and able to provide informed consent. Potential 
22 participants were emailed a link to the survey that described its purpose and procedures; persons 
23 interested in participating were asked to check a consent box before participating. The two exclusion 
24 criteria for the recruitment service were participation in a market research study of PA during the 
25 previous two months and PAG membership.
26
27 Questionnaire development and scoring
28 Questionnaire topics used for the survey were developed by the APPEAL advisory board, with the 
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1 and caregivers. The initial questionnaire draft was further developed through an interactive process, 
2 including online pilot testing with revisions made according to respondent feedback. For most survey 
3 questions, a 5-point response scale was used (in general, “1” indicated lowest impact and “5” highest). 
4 The sequence of questionnaire topics moved from clinical characteristics and practical issues of PA 
5 management to psychosocial impacts, and ended with cost (Figure 1). The scoring system was 
6 developed with reference to standard survey methods to achieve the balance between sensitivity and 
7 ease of comprehension and choice for respondents 46,47. 
8
9 Statistical analysis plan
10 There were a total of 1300 survey participants across the 8 countries (much higher than the original 
11 target of 800 participants). Given that this study was designed to be exploratory and to provide a 
12 descriptive analysis, a power calculation was not conducted. Data were summarised using descriptive 
13 statistics and presented as arithmetic means, with no weighting. Explorations of data were conducted 
14 at the pan-European level, by country, and respondent subgroups, including caregivers of PwPA 
15 reporting by proxy for PwPA, caregivers reporting for themselves, and adults with PA. Where 
16 appropriate, between-group comparisons were explored using inferential statistics (t-tests and chi 
17 square analysis). Since only descriptive analysis was conducted, no adjustments/corrections for 
18 multiple comparisons were performed. 
19
20 RESULTS
21 Study participants 
22 Between 10 November and 11 December 2017, 1300 participants (1846 total responses) from eight 
23 European countries engaged in the APPEAL-1 survey: 881 caregivers of a PwPA (720 parents and 
24 161 nonparents), of whom 546 reported by proxy for a PwPA, and 419 adults with PA (Figure 1). The 
25 number and percentage of APPEAL participants by country were generally proportionate to the 
26 relative total populations of each country (Figure 2A). Most participants were recruited via PAGs 
27 (n=829, 63.8%), with the remainder (n=471, 36.2%) recruited via the recruitment service (Figure 2B). 
28 Participants also reporting by proxy for a PwPA under their care included 401 PAG participants (for a 
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1 The proportions of participants recruited via the professional recruitment service varied widely by 
2 country (Figure 2B). Proportions of types of respondents (adults, children, parent/nonparent 
3 caregivers) were generally similar among countries although the proportion of  adults with PA (self-
4 report) ranged widely, from a high of 40% for Italy to a low of 13% for both Germany and Ireland 
5 (Figure C). The response rate from a total of 66,184 invitations via the professional recruitment 
6 service was approximately 10% (n=616 completed surveys), and varied among countries with the 
7 highest from Italy (155 from 1269 invitations) and the lowest from the United Kingdom (92 from 
8 30,794 invitations). Due to confidentiality constraints, the response rate could not be calculated for 
9 surveys distributed by PAGs. Only fully completed surveys were considered for analysis.
10
11 Demographics, food allergy prevalence and comorbid conditions 
12 Demographic and clinical characteristics of PwPA in each group (either self- or proxy-reported) are 
13 shown in Table 1. Adults with PA had a mean age of 36 years; children aged 0-3, 4-12 and 13-17 
14 years had mean ages of 2, 8, and 15 years, respectively. Most survey participants were female; this 
15 included 75% (n=315) of the 419 adults with PA. These characteristics  were similar across age 
16 groups and countries (see Table 1).
17
18 Only 28% of all responding PwPA reported being allergic exclusively to peanut; 54% reported also 
19 being allergic to tree nuts, 21% to hen’s egg, 18% to soya beans/other legumes, and 18% to cow’s 
20 milk. The five most common food allergies reported in addition to peanut, and their prevalence, 
21 varied depending on the age of the PwPA (Table 1). 
22
23 The majority of PwPA reported having a “long-term illness which limits your daily activities” (Table 
24 1). A total of 30% of adults with PA, and 28% of children and teenagers, reported having a long-term 
25 chronic, comorbid condition. The most common conditions in both adults and children/teenagers were 
26 allergic rhinitis, asthma/breathing disorders and skin disorders/eczema (Table 1).
27
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1 The survey questions did not provide for any detailed assessment of the development of PA but did 
2 assess the diagnostic and clinical evaluation history of respondents. The majority of PwPA (95%) 
3 were reported being diagnosed with PA by HCPs, most commonly allergists, a finding fairly 
4 consistent across countries and age groups (Table 2). 
5
6 The clinical evaluations used for PA diagnosis were also generally consistent across PwPA age 
7 groups and regions (Table 2). The reported methods used most frequently to confirm PA diagnosis 
8 were peanut-specific immunoglobulin E (IgE) test (53%), followed by peanut skin prick test (SPT) 
9 (50%); 29% of respondents reported that they received diagnosis confirmation with both IgE and 
10 peanut SPT (Table 2). Additionally, 6% reported their first PA diagnosis was based on the combined 
11 results of IgE, peanut SPT, and oral food challenge. 
12
13 Importantly, 95% of all PwPA reported having an allergic reaction to peanut. This percentage was 
14 consistent across all age groups . The mean age of PA diagnosis reported among all PwPA was 8.9 
15 years but variability was seen among adults (15.9 years), children aged 0-3 (1.4), children 4-12 years 
16 (3.1) and teenagers 13-17 years (4.4) (Table 2). These ages generally coincided with the mean age of 
17 first allergic reaction to peanut in each of the age groups (Table 2). 
18
19 Peanut allergic reactions, severity and inconvenience
20 A total of 38% of all PwPA reported (by self or proxy) that they visited an HCP in the last six months 
21 regarding their peanut allergy (Table 3). Amongst PwPA, 9% reported that their worst allergic 
22 reaction occurred within the past year, most commonly in children aged 0-3 years (27%). For close to 
23 half of PwPA (45%), their worst allergic reaction was rated as severe. Almost one-third of 
24 respondents (31%) said their worst PA reaction required hospitalisation and emergency medication; 
25 percentages were higher in all younger age groups (children and teenagers, 35% to 42%) compared 
26 with adults (26%). Overall percentages were 7% for those reporting hospitalisation only and 36% for 
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1 Among all PwPA who reported on their worst allergic reaction to peanut, most reported more than 
2 one symptom (87.4%); 142 (12.6%) reported only one symptom. The most common symptoms 
3 reported included swelling (e.g. lips, eyes, and/or tongue) (58%), breathing difficulties/wheezing 
4 (50%), itching mouth/throat tightness (50%), and itching of the skin, eyes, and/or nose (38%). 
5 Gastrointestinal symptoms were reported by almost one-third of respondents (vomiting 30%, nausea 
6 27%, stomach pain/cramps 24%), and dizziness and fainting/collapsing were reported by 13% and 9% 
7 of respondents, respectively. Anxiety, reported by 25% of respondents, was always accompanied by 
8 other symptoms of a reaction (it was never the only symptom), regardless of the age of the PwPA 
9 reporting group or the region (Table 3).
10
11 Among all PwPA who reported the circumstances of their worst reaction to peanut, almost one-third 
12 (31%) said they received no support or PA management advice/support from HCPs following the 
13 reaction; only one-third (33%) said they received training on how to use emergency medication; and 
14 approximately only a quarter (27%) received training on what to do in an emergency (Table 3). Also, 
15 only 14% said they received information about patient associations for food allergy and anaphylaxis 
16 prevention. Similar responses for these parameters were observed among age groups and countries 
17 (Table 3). 
18
19 Care and management
20 Among all PwPA, more than one-quarter (28%) reported having not been prescribed an AAI for PA 
21 reaction treatment, varying from 11% for children aged 4-12 years, 44% for adults, and 22% for 
22 teenagers (Table 4). Of all those prescribed an AAI (n=897), two-thirds (66%) had never used it, 
23 ranging from 52% in adults to 86% in younger children (aged 0-3 years) (Table 4). Among PwPA 
24 who were prescribed an AAI, the highest rate of complete satisfaction with the training they received 
25 for using it (score of 5 on a scale of 1-5) was 27%, seen in adults and in teenagers (Table 4). 
26
27 Rates of AAI prescription also varied by the main symptoms of a worst allergic reaction. Among 
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1 eyes, and/or tongue), itching of the mouth/throat tightness, or difficulties breathing/wheezing during 
2 their worst allergic reaction. 
3
4 Costs of living with PA
5 Almost half of all respondents (46%) stated that living with PA was “more” (33%) or “much more” 
6 (13%) expensive (versus not living with PA). Percentages who reported that living with PA was 
7 “much more” expensive varied among age groups, including 20% of respondents for children aged 0-
8 3 years, 10% of adults and 17% of respondents for teenagers (aged 13-17 years). Most respondents 
9 also described as “significant” the indirect costs of the extra time needed for planning day-to-day 
10 activities (85%) and special events (91%), with similar rates across age groups. 
11
12 See Supporting Materials for a video of results from APPEAL-1.
13
14 DISCUSSION
15 The purpose of the APPEAL-1 survey, carried out across eight European countries, was to investigate 
16 and evaluate the personal perceptions, experiences, burdens and impacts of living with PA. To this 
17 end, a 50-question survey assessing PwPA and caregivers’ knowledge, experience and satisfaction 
18 was developed by an expert panel. In the current article, we provide demographic and clinical history 
19 data for multiple respondent groups, including children, teenagers and adults with PA. These data 
20 provide essential insight and data on PA diagnosis, comorbidities, severity of symptoms, 
21 management, and other clinical factors. In a companion paper in this issue of Allergy, the 
22 psychosocial and quality-of-life impacts of PA are also reported.45 
23
24 The overall demographics, PA symptoms, other food allergies, and coexistence of other allergic 
25 conditions in the adult and children/teenager groups in this survey were generally consistent with 
26 other population studies on PA.26,48 Previous studies in European and Canadian pediatric cohorts have 
27 reported a younger mean age of diagnosis (approximately 3 years),26,49 than the overall age of 
28 diagnosis reported in APPEAL-1 (8.9 years), although similar to the ages reported for the pediatric 
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1 of diagnosis reported by adults. Of note, adults may have recall bias towards older ages in reporting 
2 peanut allergy history whereas caregivers reporting by proxy may more accurately remember the 
3 more recent dates of peanut allergy diagnosis in their children.50 The rates of children with a history 
4 of asthma, atopic dermatitis and/or eczema in our study (Table 1) are similar to those observed in 
5 other paediatric PA populations.14,26,44 PwPA are often advised to avoid tree nuts, either because of an 
6 allergy to them, the potential for cross-reactivity or -contamination, or uncertainty over the ability of 
7 PwPA and caregivers (especially nonparent) to distinguish tree nuts from peanuts.51 The APPEAL-1 
8 survey showed that up to 53% of PwPA reported allergy to one or more tree nuts, which is also 
9 consistent with previous findings.26,52 Several previous studies reported that PA was more common in 
10 male children (>60%) 26,44,51,52 while the APPEAL-1 survey population included more female children 
11 with PA (54%); however, one other multinational study also reported a slight majority of females in a 
12 randomly selected PA population.53 Women may also be more inclined than men to participate in 
13 healthcare surveys in general.54 
14
15 Our data on diagnostic testing also support previous findings. The APPEAL-1 survey confirms that 
16 PA is generally diagnosed early in childhood, similar to data reported in other European/multinational 
17 studies.26,53 The survey analysis also showed that more than half of PwPA (53%) had their PA 
18 diagnosis confirmed via IgE, and 29% received both IgE and SPT, which validated the presence of 
19 PA in the survey population. Only 12% reported having an oral food challenge, which is typically 
20 used to confirm diagnosis when clinical history is ambiguous or nonexisting.55 Approximately 10% of 
21 respondents said they had never experienced a reaction to peanut despite being diagnosed with PA. 
22 Such respondents may have been tested for PA despite their lack of reaction history, with resulting 
23 diagnosis, based on risk factors such as other allergic conditions (egg allergy or atopic eczema) or 
24 having a family member with PA.49,56 In addition, study data show that only a minority of patients 
25 who have a positive SPT or specific IgE but no known exposure to peanut may have clinical PA.4 
26 Taken together, these data suggest that a clearly defined clinical history of PA is still required, as well 











This article is protected by copyright. All rights reserved
1 With regard to PA management and clinical care, 28% of PwPA had never been prescribed an AAI, 
2 and approximately one-quarter (24%) of those prescribed an AAI were either not at all satisfied with 
3 their training for it or received no training. These data were similar across the countries surveyed, 
4 suggesting a widespread need in Europe for improved quality of PA health management and 
5 education concerning AAI use. This view is supported by a recent 10-year study of 10,184 cases of 
6 anaphylaxis in the European Anaphylaxis Registry, which found that only 27.1% of patients treated 
7 by an HCP received adrenaline “despite clear recommendations” indicating this therapy for 
8 anaphylaxis.59 In addition, a study of all food-related anaphylactic deaths in the UK for the period of 
9 1999-2006, including 48 deaths, 9 of which were related to peanut, found that only 40% of those who 
10 died had been provided AAIs, and less than half had received HCP advice on managing their food 
11 allergy.19 Marked underuse of AAI for anaphylaxis, at variance with current anaphylaxis management 
12 guidelines, has also been reported in Germany.60-62
13
14 Almost half of respondents reported that PA caused additional living expense, and large majorities 
15 cited a cost of extra time for planning of routine and special activities. A EuroPrevall study previously 
16 reported that mean annual healthcare costs (international dollars) were increased by I$927 for adults 
17 and I$1334 for children with food allergy, compared with age-matched controls, across 12 European 
18 countries for the period from 2007 to 2009.63 It is clear that more research is necessary to understand 
19 and determine how to reduce the financial and economic burden for PwPA living in Europe. 
20
21 Limitations of the APPEAL-1 survey include use of a self-selecting sample from invitation, which 
22 may introduce selection bias, as no randomisation was conducted (e.g., individuals who.  
23 perceived/experienced greater impact of PA on themselves/their children may have been more likely 
24 to participate in this study versus those who felt less impact). The 2 recruitment methods used may 
25 also have influenced the study results since, hypothetically, PAG participants may be more likely to 
26 be motivated by emotions associated with PA and panel participants may have greater financial 
27 incentive because they received such compensation. Although 5% of PwPA had not been diagnosed 
28 with PA by an HCP and 10% had not experienced a reaction to peanut, the inclusion of such 









This article is protected by copyright. All rights reserved
1 study cohort and may better reflect the composition of the real-world population affected by PA than 
2 a more restricted cohort. As with many questionnaire surveys, there was a risk of recall bias on 
3 several questions (e.g. regarding “worst allergic reaction” and ages at first reaction and diagnosis). 
4 Descriptions and assessments of some parameters, such as severity of reaction, may also differ 
5 between survey respondents and HCPs. Additionally, because the survey was translated from English 
6 into 6 additional languages, there may have been some heterogeneity in interpretations of some 
7 questions and in the resulting responses across regions. 
8
9 PwPA, families, and caregivers faced with the diagnosis of PA encounter many challenges and much 
10 uncertainty. APPEAL-1 provides a functional basis for greater understanding of PA characteristics, 
11 management, and impact on PwPA and caregivers across Europe. The results suggest that challenges 
12 facing PwPA, such as the need for sufficient education on disease management, are similar across 
13 Europe. Findings on the psychosocial and HRQL impacts of PA on the respondents in this study are 
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TABLES











































































   Female



























Diagnosed with PA only,a % 28 24 39 33 28 33 24 34 13 24 27 15 47
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Celery







Seeds (e.g. poppy, sunflower)
Sesame
Shellfish/crustacean/molluscs








































































































































































































Allergic rhinitis (hay fever)






Mood disorders / depression













































































































































aNo other reported food allergies; bSubjects were instructed to select all that applied from a list. 
HCP, healthcare professional; PA, peanut allergy; PwPA, persons with peanut allergy; SD, standard deviation; UK, United Kingdom.
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Table 2.  Peanut allergy diagnostics in PwPA 
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(12.3) (14.9)  (0.6) (2.2) (3.7) (16.2) (13.2) (10.2) (12.1) (8.4) (9.6) (13.2) (12.8)


























HCP making first diagnosis, % 
   Allergist (paediatric or general)
   Emergency doctor
   Paediatrician
   Immunologist/immunology specialist
   Primary care/family/GP
   Nurse (allergy, other)









































































































Method of diagnosis,a % 
Clear clinical reaction to PA
SPT to peanut
Blood test (IgE to peanut)
OFC in hospital/clinic
Both SPT and IgE
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Both IgE and OFC





















































aSubjects were instructed to select all that applied from a list of single diagnostic methods. 
GP, general practitioner; HCP, healthcare professional; IgE, immunoglobulin E; OFC, oral food challenge; PA, peanut allergy; PwPA, persons with peanut allergy; SD, standard 
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Table 3. Peanut Allergy Reaction and Treatment History





















Denmark France Germany Italy Ireland Netherlands Spain UK 
Last saw HCP about PA, % 
   > 5 years ago
   last 2 to 5 years
   last 1 – 2 years
   last 6 – 12 months















































































Worst reaction with PA (all not in a 
clinical trial, %)
   > 5 years ago
   last 2 to 5 years
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   last 1 – 2 years
   last 6 – 12 months








































Severity rating of worst allergic 
reaction to peanut, % 
   Severe
   Moderate
   Mild


































































Healthcare for worst allergic 
reaction to peanut,a % (n=1128)
   Both hospitalisation and EM
   Hospitalisation only
   EM only 
   No, neither















































































Main symptoms for worst allergic 
reaction to peanut,b % (n=1593)
Nausea
(n=1128)
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Vomiting
Heartburn / bloating
Stomach pain / cramps
Indigestion
Diarrhoea
Breathing difficulties / wheezing
Anxiety
Tiredness (acute or sudden)
Fainting / collapsing
Dizziness
Swelling (e.g. lips, eyes, and/or 
tongue)
Itching mouth / throat tightness
Eczema flare / rashes
Hives




































































































































































































Advice/support offered after worst 
allergic reaction to peanut, % 
(n=1128)a




(n=48)            
23
(n=378)            
28
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   None
   Training on use of EM
   Training in case of emergency
   Psychological Counselling
   Information about PA associations


































































aSubjects were instructed to pick one of the choices shown; bSubjects were instructed to select all that applied. 
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Table 4.  Care management for PA





















Denmark France Germany Italy Ireland The 
Netherlands
Spain UK
Prescribed an AAI?, %
   Yes
   No





















































Time since AAI last used, %  
   <6 months ago
   6-12 months ago
   1-2 years ago
   2-5 years ago
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   Never 66 52 86 77 60 77 63 81 47 54 53 72 64
Satisfaction with training on use 
of AAIs (on scale of 1 – 5), %a
   1 - Completely satisfied
   2 
   3
   4
   5 - Not at all satisifed




























































































aThe respondent base for this question is PwPA who have been prescribed an AAI + their parents/carers
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FIGURES
Figure 1. APPEAL-1 questionnaire structure and respondent groupings. (A) Question categories. (B) 
Flow chart shows the number of subjects surveyed and number of responses from each population. 
(C) Number of respondents from each age group (self- or proxy-reported). 
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Figure 2. Respondents by country (A), recruitment source (B), and type (C) (adult with PA self-
report; parent/caregiver of PwPA self-report; parent/nonparent caregiver proxy-report for person with 









PAGs, patient advocacy groups; UK, United Kingdom. 
